Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
4 "Metabolic diseases"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Articles
Diabetes, Obesity and Metabolism
Human Tissue-Engineered Skeletal Muscle: A Tool for Metabolic Research
Ji-Hoon Kim, Seung-Min Yu, Jang Won Son
Endocrinol Metab. 2022;37(3):408-414.   Published online June 29, 2022
DOI: https://doi.org/10.3803/EnM.2022.302
  • 3,795 View
  • 160 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Skeletal muscle is now regarded as an endocrine organ based on its secretion of myokines and exerkines, which, in response to metabolic stimuli, regulate the crosstalk between the skeletal muscle and other metabolic organs in terms of systemic energy homeostasis. This conceptual basis of skeletal muscle as a metabolically active organ has provided insights into the potential role of physical inactivity and conditions altering muscle quality and quantity in the development of multiple metabolic disorders, including insulin resistance, obesity, and diabetes. Therefore, it is important to understand human muscle physiology more deeply in relation to the pathophysiology of metabolic diseases. Since monolayer cell lines or animal models used in conventional research differ from the pathophysiological features of the human body, there is increasing need for more physiologically relevant in vitro models of human skeletal muscle. Here, we introduce recent studies on in vitro models of human skeletal muscle generated from adult myogenic progenitors or pluripotent stem cells and summarize recent progress in the development of three-dimensional (3D) bioartificial muscle, which mimics the physiological complexity of native skeletal muscle tissue in terms of maturation and functionality. We then discuss the future of skeletal muscle 3D-organoid culture technology in the field of metabolic research for studying pathological mechanisms and developing personalized therapeutic strategies.

Citations

Citations to this article as recorded by  
  • Human‐based new approach methodologies to accelerate advances in nutrition research
    Manuela Cassotta, Danila Cianciosi, Maria Elexpuru‐Zabaleta, Inaki Elio Pascual, Sandra Sumallo Cano, Francesca Giampieri, Maurizio Battino
    Food Frontiers.2024;[Epub]     CrossRef
Close layer
Diabetes-Related Cardiac Dysfunction
Lamario J. Williams, Brenna G. Nye, Adam R. Wende
Endocrinol Metab. 2017;32(2):171-179.   Published online June 23, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.2.171
  • 10,971 View
  • 44 Download
  • 37 Web of Science
  • 36 Crossref
AbstractAbstract PDFPubReader   ePub   

The proposal that diabetes plays a role in the development of heart failure is supported by the increased risk associated with this disease, even after correcting for all other known risk factors. However, the precise mechanisms contributing to the condition referred to as diabetic cardiomyopathy have remained elusive, as does defining the disease itself. Decades of study have defined numerous potential factors that each contribute to disease susceptibility, progression, and severity. Many recent detailed reviews have been published on mechanisms involving insulin resistance, dysregulation of microRNAs, and increased reactive oxygen species, as well as causes including both modifiable and non-modifiable risk factors. As such, the focus of the current review is to highlight aspects of each of these topics and to provide specific examples of recent advances in each area.

Citations

Citations to this article as recorded by  
  • Upregulation of PCSK9, rho kinase and cardiac troponin by Eucalyptus globulus leaf extract improves fructose-streptozotocin-induced diabetic cardiac dysfunction in rats
    Afolabi C. Akinmoladun, Morenikejimi Bello, Emmanuel Oluwafemi Ibukun
    Archives of Physiology and Biochemistry.2023; 129(6): 1219.     CrossRef
  • An Overview of Cardiotonic Medicinal Plants from the Perspective of Iranian Traditional Medicine
    Akram Alembagheri, Homa Hajimehdipoor, Rasool Choopani, Somayeh Esmaeili
    Jundishapur Journal of Natural Pharmaceutical Products.2023;[Epub]     CrossRef
  • Nanoformulations for the Delivery of Dietary Anthocyanins for the Prevention and Treatment of Diabetes Mellitus and Its Complications
    Ana R. Nunes, Elisabete C. Costa, Gilberto Alves, Luís R. Silva
    Pharmaceuticals.2023; 16(5): 736.     CrossRef
  • Cyp2e1 knockdown attenuates high glucose-induced apoptosis and oxidative stress of cardiomyocytes by activating PI3K/Akt signaling
    Jianying Wang, Han Yang, Chao Wang, Cuie Kan
    Acta Diabetologica.2023; 60(9): 1219.     CrossRef
  • Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value
    Yu-Qi Li, Lei Xin, Yu-Chi Zhao, Shang-Qi Li, Ya-Nuo Li
    World Journal of Hepatology.2023; 15(6): 786.     CrossRef
  • Non-Invasive Assessment of the Intraventricular Pressure Using Novel Color M-Mode Echocardiography in Animal Studies: Current Status and Future Perspectives in Veterinary Medicine
    Ahmed S. Mandour, Ahmed Farag, Mahmoud A. Y. Helal, Gamal El-Masry, Salim Al-Rejaie, Ken Takahashi, Tomohiko Yoshida, Lina Hamabe, Ryou Tanaka
    Animals.2023; 13(15): 2452.     CrossRef
  • Diet‐induced prediabetes: Effects on the activity of the renin–angiotensin–aldosterone system in selected organs
    Bongeka Cassandra Mkhize, Palesa Mosili, Phikelelani Sethu Ngubane, Ntethelelo Hopewell Sibiya, Andile Khathi
    Journal of Diabetes Investigation.2022; 13(5): 768.     CrossRef
  • Knowledge domain and emerging trends in diabetic cardiomyopathy: A scientometric review based on CiteSpace analysis
    Shiyi Tao, Deshuang Yang, Lanxin Zhang, Lintong Yu, Zihan Wang, Lingling Li, Jin Zhang, Ruiqi Yao, Li Huang, Mingjing Shao
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
    Joshua J Neumiller, Fredrick J Lienhard, Radica Z Alicic, Katherine R Tuttle
    European Endocrinology.2022; 18(2): 106.     CrossRef
  • Protective effects of medicinal plant against diabetes induced cardiac disorder: A review
    Sadegh Shabab, Zahra Gholamnezhad, Maryam Mahmoudabady
    Journal of Ethnopharmacology.2021; 265: 113328.     CrossRef
  • Toward a broader view of mechanisms of drug cardiotoxicity
    Polina Mamoshina, Blanca Rodriguez, Alfonso Bueno-Orovio
    Cell Reports Medicine.2021; 2(3): 100216.     CrossRef
  • Cardioprotective Effect of Glycyrrhizin on Myocardial Remodeling in Diabetic Rats
    Vikram Thakur, Narah Alcoreza, Monica Delgado, Binata Joddar, Munmun Chattopadhyay
    Biomolecules.2021; 11(4): 569.     CrossRef
  • Cardioprotective Action of Glycyrrhizin on Diabetic Rats with Myocardial Remodeling
    Fuxu Chen, Jie Song, Enas Abdulhay
    Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
  • Management of inflammation in cardiovascular diseases
    Sumanta Kumar Goswami, Prabhat Ranjan, Roshan Kumar Dutta, Suresh Kumar Verma
    Pharmacological Research.2021; 173: 105912.     CrossRef
  • Diabetic Cardiomyopathy: Clinical and Metabolic Approach
    Dragan B. Djordjevic, Goran Koracevic, Aleksandar D. Djordjevic, Dragan B. Lovic
    Current Vascular Pharmacology.2021; 19(5): 487.     CrossRef
  • Effect of Acute Chemotherapy on Glucose Levels in Rats
    Ahmad H. Alhowail, Gena S. Alfawzan, Maha A. Aldubayan, Lolwah S. Alsalam
    International Journal of Pharmacology.2020; 16(3): 276.     CrossRef
  • Transplantation of adipose tissue lacking PAI-1 improves glucose tolerance and attenuates cardiac metabolic abnormalities in high-fat diet-induced obesity
    Sijing Liu, Yi Li, Xin Fan, Kai Li, Chunrong Xu, Liping Zhang, Mao Luo, Liqun Wang, Rong Li, Jianbo Wu
    Adipocyte.2020; 9(1): 170.     CrossRef
  • Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
    Jeffrey I. Mechanick, Michael E. Farkouh, Jonathan D. Newman, W. Timothy Garvey
    Journal of the American College of Cardiology.2020; 75(5): 525.     CrossRef
  • Associated Targets of the Antioxidant Cardioprotection of Ganoderma lucidum in Diabetic Cardiomyopathy by Using Open Targets Platform: A Systematic Review
    Fahmi Shaher, Hongbin Qiu, Shuqiu Wang, Yu Hu, Weiqun Wang, Yu Zhang, Yao Wei, Hisham AL-ward, Mahfoudh A. M. Abdulghani, Sattam Khulaif Alenezi, Salem Baldi, Shaobo Zhou
    BioMed Research International.2020; 2020: 1.     CrossRef
  • Human trophoblast-derived exosomes attenuate doxorubicin-induced cardiac injury by regulating miR-200b and downstream Zeb1
    Jie Ni, Yihai Liu, Lina Kang, Lian Wang, Zhonglin Han, Kun Wang, Biao Xu, Rong Gu
    Journal of Nanobiotechnology.2020;[Epub]     CrossRef
  • Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists
    Emily J Cox, Radica Z Alicic, Joshua J Neumiller, Katherine R Tuttle
    US Endocrinology.2020; 16(2): 80.     CrossRef
  • Hyperbaric Oxygen Therapy Dampens Inflammatory Cytokine Production and Does Not Worsen the Cardiac Function and Oxidative State of Diabetic Rats
    Rita Benkő, Zsuzsanna Miklós, Viktor Antal Ágoston, Katrine Ihonvien, Csaba Répás, Roland Csépányi-Kömi, Margit Kerék, Nóra Judit Béres, Eszter Mária Horváth
    Antioxidants.2019; 8(12): 607.     CrossRef
  • Heart Failure in Type 2 Diabetes Mellitus
    Helena C. Kenny, E. Dale Abel
    Circulation Research.2019; 124(1): 121.     CrossRef
  • SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
    Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, Ann-Cathrine Jönsson-Rylander
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Depressive symptoms in asymptomatic stage B heart failure with Type II diabetic mellitus
    Paul J. Mills, Pam R. Taub, Ottar Lunde, Meredith A. Pung, Kathleen Wilson, Christopher Pruitt, Thomas Rutledge, Alan Maisel, Barry H. Greenberg
    Clinical Cardiology.2019; 42(6): 637.     CrossRef
  • Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate
    Amir M. Al Hroob, Mohammad H. Abukhalil, Omnia E. Hussein, Ayman M. Mahmoud
    Biomedicine & Pharmacotherapy.2019; 109: 2155.     CrossRef
  • The Janus face of HMGB1 in heart disease: a necessary update
    Angela Raucci, Stefania Di Maggio, Francesco Scavello, Alessandro D’Ambrosio, Marco E. Bianchi, Maurizio C. Capogrossi
    Cellular and Molecular Life Sciences.2019; 76(2): 211.     CrossRef
  • Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model
    Sabri Sudirman, Ching-Shu Lai, Yi-Ling Yan, Hung-I Yeh, Zwe-Ling Kong
    Scientific Reports.2019;[Epub]     CrossRef
  • Microarray profiling analysis identifies the mechanism of miR‐200b‐3p/mRNA‐CD36 affecting diabetic cardiomyopathy via peroxisome proliferator activated receptor‐γ signaling pathway
    Liqiong Xu, Wei Chen, Min Ma, Anfang Chen, Chengyue Tang, Chengwei Zhang, Lin Cai
    Journal of Cellular Biochemistry.2019; 120(4): 5193.     CrossRef
  • Plasma Low-Density Lipoprotein Cholesterol Correlates With Heart Function in Individuals With Type 2 Diabetes Mellitus: A Cross-Sectional Study
    Po-Chung Cheng, Shang-Ren Hsu, Jung-Chi Li, Ching-Pei Chen, Szu-Chi Chien, Shih-Te Tu, Yun-Chung Cheng, Yu-Hsiu Liu, Jeng-Fu Kuo
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • Impact of diabetes mellitus on the contractile properties of the left and right atrial myofilaments†
    Constanze Bening, Khaled Alhussini, Elena-Aura Mazalu, Jonathan Yaqub, Khaled Hamouda, Dejan Radakovic, Christoph Schimmer, Grzegorz Hirnle, Rainer Leyh
    European Journal of Cardio-Thoracic Surgery.2018; 54(5): 826.     CrossRef
  • LAZ3 protects cardiac remodeling in diabetic cardiomyopathy via regulating miR-21/PPARa signaling
    Lu Gao, Yuan Liu, Sen Guo, Lili Xiao, Leiming Wu, Zheng Wang, Cui Liang, Rui Yao, Yanzhou Zhang
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2018; 1864(10): 3322.     CrossRef
  • Gene expression profiles of rat MMECs with different glucose levels and fgl2 gene silencing
    Zhenzhong Zheng, Fan Zhang, Dengpeng Gao, Yujing Wu, Hao Wu
    Diabetes/Metabolism Research and Reviews.2018;[Epub]     CrossRef
  • Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
    Kwong-Man Ng, Yee-Man Lau, Vidhu Dhandhania, Zhu-Jun Cai, Yee-Ki Lee, Wing-Hon Lai, Hung-Fat Tse, Chung-Wah Siu
    Scientific Reports.2018;[Epub]     CrossRef
  • Apelin‑13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high‑fat diet
    Meng Li, Huijuan Fang, Jian Hu
    Molecular Medicine Reports.2018;[Epub]     CrossRef
  • Adriamycin-induced cardiomyopathy can serve as a model for diabetic cardiomyopathy – a hypothesis
    Kaviyarasi Renu, V.G. Abilash, P.B. Tirupathi Pichiah, Thabassum Akthar Syeda, Sankarganesh Arunachalam
    Asian Pacific Journal of Tropical Biomedicine.2017; 7(11): 1041.     CrossRef
Close layer
Recent Insights into Insulin-Like Growth Factor Binding Protein 2 Transcriptional Regulation
Minsang Shin, Hye Suk Kang, Jae-Hyung Park, Jae-Hoon Bae, Dae-Kyu Song, Seung-Soon Im
Endocrinol Metab. 2017;32(1):11-17.   Published online January 19, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.1.11
  • 4,837 View
  • 65 Download
  • 21 Web of Science
  • 23 Crossref
AbstractAbstract PDFPubReader   

Insulin-like growth factor binding proteins (IGFBPs) are major regulators of insulin-like growth factor bioavailability and activity in metabolic signaling. Seven IGFBP family isoforms have been identified. Recent studies have shown that IGFBPs play a pivotal role in metabolic signaling and disease, including the pathogenesis of obesity, diabetes, and cancer. Although many studies have documented the various roles played by IGFBPs, transcriptional regulation of IGFBPs is not well understood. In this review, we focus on the regulatory mechanisms of IGFBP gene expression, and we summarize the findings of transcription factor activity in the IGFBP promoter region.

Citations

Citations to this article as recorded by  
  • Predictive potential of various plasma inflammation-, angiogenesis-, and extracellular matrix remodeling-associated mediators for intra-amniotic inflammation and/or microbial invasion of the amniotic cavity in preterm labor
    Eunwook Joo, Subeen Hong, Kyo Hoon Park, Hyeon Ji Kim, Min Jung Lee, Sue Shin
    Archives of Gynecology and Obstetrics.2024;[Epub]     CrossRef
  • Loss of IGFBP2 mediates alveolar type 2 cell senescence and promotes lung fibrosis
    Chiahsuan Chin, Ranjithkumar Ravichandran, Kristina Sanborn, Timothy Fleming, Stephen B. Wheatcroft, Mark T. Kearney, Sofya Tokman, Rajat Walia, Michael A. Smith, David J. Flint, Thalachallour Mohanakumar, Ross M. Bremner, Angara Sureshbabu
    Cell Reports Medicine.2023; 4(3): 100945.     CrossRef
  • Circulating IGF-1 and IGFBP-2 may be biomarkers for risk stratification in patients with acute coronary syndrome: A prospective cohort study
    Wei Wang, Ying Sun, De-Gang Mo, Tai Li, Heng-Chen Yao
    Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(9): 1740.     CrossRef
  • Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells
    Yilin Xiong, Yan Wang, Tao Yang, Yunmei Luo, Shangfu Xu, Lisheng Li
    American Journal of Cardiovascular Drugs.2023; 23(5): 497.     CrossRef
  • Octopus death and dying
    Z Yan Wang
    Integrative And Comparative Biology.2023; 63(6): 1209.     CrossRef
  • Efficient generation of functional pancreatic β cells from dental-derived stem cells via laminin-induced differentiation
    Riham M. Aly, Hadeer A. Aglan, Ghada Nour Eldeen, Nadia S. Mahmoud, Eman H. Aboul-Ezz, Hanaa H. Ahmed
    Journal of Genetic Engineering and Biotechnology.2022; 20(1): 85.     CrossRef
  • Insulin-like growth factor signalling and its significance as a biomarker in fish and shellfish research
    S. Chandhini, Bushra Trumboo, Seena Jose, Tincy Varghese, M. Rajesh, V. J. Rejish Kumar
    Fish Physiology and Biochemistry.2021; 47(4): 1011.     CrossRef
  • Nanomaterials for Chronic Kidney Disease Detection
    Solmaz Maleki Dizaj, Aziz Eftekhari, Shakar Mammadova, Elham Ahmadian, Mohammadreza Ardalan, Soodabeh Davaran, Aygun Nasibova, Rovshan Khalilov, Mahbuba Valiyeva, Sevil Mehraliyeva, Ebrahim Mostafavi
    Applied Sciences.2021; 11(20): 9656.     CrossRef
  • Producción de las proteínas de unión al factor de crecimiento insulinoide durante el desarrollo de la fibrosis hepática por hepatitis C crónica
    D. Rosique-Oramas, M. Martínez-Castillo, A. Raya, Z. Medina-Ávila, F. Aragón, J. Limón-Castillo, A. Hernández-Barragán, A. Santoyo, E. Montalvo-Javé, J.L. Pérez-Hernández, F. Higuera-de la Tijera, A. Torre, D. Kershenobich, G. Gutiérrez-Reyes
    Revista de Gastroenterología de México.2020; 85(4): 390.     CrossRef
  • Interacción cardiorrenal y evolución de la insuficiencia cardiaca. ¿Tiene un papel la proteína de unión del factor de crecimiento de tipo insulina 2?
    Susana Ravassa, Javier Beaumont, Germán Cediel, Josep Lupón, Begoña López, Ramón Querejeta, Javier Díez, Antoni Bayés-Genís, Arantxa González
    Revista Española de Cardiología.2020; 73(10): 835.     CrossRef
  • Molecular identification of grass carp igfbp2 and the effect of glucose, insulin, and glucagon on igfbp2 mRNA expression
    Guokun Yang, Wenli Zhao, Chaobin Qin, Liping Yang, Xiaolin Meng, Ronghua Lu, Xiao Yan, Xianglin Cao, Yanmin Zhang, Guoxing Nie
    Fish Physiology and Biochemistry.2020; 46(4): 1469.     CrossRef
  • Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C
    D. Rosique-Oramas, M. Martínez-Castillo, A. Raya, Z. Medina-Ávila, F. Aragón, J. Limón-Castillo, A. Hernández-Barragán, A. Santoyo, E. Montalvo-Javé, J.L. Pérez-Hernández, F. Higuera-de la Tijera, A. Torre, D. Kershenobich, G. Gutiérrez-Reyes
    Revista de Gastroenterología de México (English Edition).2020; 85(4): 390.     CrossRef
  • Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?
    Susana Ravassa, Javier Beaumont, Germán Cediel, Josep Lupón, Begoña López, Ramón Querejeta, Javier Díez, Antoni Bayés-Genís, Arantxa González
    Revista Española de Cardiología (English Edition).2020;[Epub]     CrossRef
  • Integration of single-cell datasets reveals novel transcriptomic signatures of β-cells in human type 2 diabetes
    Emanuele Bosi, Lorella Marselli, Carmela De Luca, Mara Suleiman, Marta Tesi, Mark Ibberson, Decio L Eizirik, Miriam Cnop, Piero Marchetti
    NAR Genomics and Bioinformatics.2020;[Epub]     CrossRef
  • Transcriptional Analysis of FOXO1, C/EBP- and PPAR-2 Genes and Their association with Obesity-Related Insulin Resistance
    Boughanem, Cabrera-Mulero, Millán-Gómez, Garrido-Sánchez, Cardona, Tinahones, Moreno-Santos, Macías-González
    Genes.2019; 10(9): 706.     CrossRef
  • Immune biomarkers in maternal plasma to identify histologic chorioamnionitis in women with preterm labor
    Jeong Woo Park, Kyo Hoon Park, Song Yi Kook, Young Mi Jung, Yu Mi Kim
    Archives of Gynecology and Obstetrics.2019; 299(3): 725.     CrossRef
  • Insulin like growth factor binding protein 2 (IGFBP-2) for risk prediction in patients with severe aortic stenosis undergoing Transcatheter Aortic Valve Implantation (TAVI)
    Johanna Maria Muessig, Michael Lichtenauer, Bernhard Wernly, Malte Kelm, Marcus Franz, Laura Bäz, Paul Christian Schulze, Victoria Racher, Georg Zimmermann, Hans-Reiner Figulla, Vera Paar, Uta C. Hoppe, Philippe Rouet, Alexander Lauten, Christian Jung
    International Journal of Cardiology.2019; 277: 54.     CrossRef
  • Molecular cloning and expression pattern of IGFBP-2a in black porgy (Acanthopagrus schlegelii) and evolutionary analysis of IGFBP-2s in the species of Perciformes
    Xinyi Zhang, Zhiyong Zhang, Zhenpeng Yu, Jiayi Li, Shuyin Chen, Ruijian Sun, Chaofeng Jia, Fei Zhu, Qian Meng, Shixia Xu
    Fish Physiology and Biochemistry.2019; 45(5): 1731.     CrossRef
  • Current Insights into the Role of the Growth Hormone-Insulin-Like Growth Factor System in Short Children Born Small for Gestational Age
    Judith S. Renes, Jaap van Doorn, Anita C.S. Hokken-Koelega
    Hormone Research in Paediatrics.2019; 92(1): 15.     CrossRef
  • Insulin-Like Growth Factor (IGF) System in Liver Diseases
    Agnieszka Adamek, Aldona Kasprzak
    International Journal of Molecular Sciences.2018; 19(5): 1308.     CrossRef
  • IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI
    Hai-Lun Li, Zhuan Yan, Zun-Ping Ke, Xiao-Feng Tian, Li-Li Zhong, Yong-Tao Lin, Yong Xu, Dong-Hui Zheng
    Oncotarget.2018; 9(93): 36551.     CrossRef
  • Multiple optic gland signaling pathways implicated in octopus maternal behaviors and death
    Z. Yan Wang, Clifton W. Ragsdale
    Journal of Experimental Biology.2018;[Epub]     CrossRef
  • Insulin-Like Growth Factor-Binding Proteins of Teleost Fishes
    Daniel Garcia de la Serrana, Daniel J. Macqueen
    Frontiers in Endocrinology.2018;[Epub]     CrossRef
Close layer
Original Article
Association between Non-alcoholic Fatty Liver and Metabolic Diseases.
Hong Kyu Kim, Chan Jong Suh, Hyo Joong Yoon, Yong Ha Hwang, Kee Young Lee, Hye Young Park, Kap Hwan Kim, Moon Ho Kang
J Korean Endocr Soc. 2002;17(4):526-534.   Published online August 1, 2002
  • 1,123 View
  • 24 Download
AbstractAbstract PDF
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is known to be frequently associated with obesity, type 2 diabetes and dyslipidemia. Recently, the diagnosis of fatty liver disease, based on ultrasonographic findings, has increased. Therefore, we examined the association between NAFLD and various metabolic diseases, such as obesity, glucose intolerance, dyslipidemia, and hypertension or metabolic syndrome, and tried to find out whether NAFLD was independently related to insulin resistance. METHODS: From April to June 2000, 262 subjects, attending for routine physical check-ups, were screened. Of these, 115 one hundred fifteen subjects were studied, with the other 147 excluded due to significant alcohol consumption, evidence of viral or toxic hepatitis, significant liver or renal dysfunction, and overt thyroid disease. Fatty liver was diagnosed if the subject had a "bright" liver on ultrasonographic examination. All diagnoses were made by a single experienced radiologist. RESULTS: Of the 115 subjects. 30 (26%) showed NAFLD. 1. Systolic and diastolic blood pressures, body weight, serum total cholesterol, triglyceride, fasting insulin levels and HOMA IR (homeostasis model assessment insulin resistance index) were higher in the subjects with NAFLD than in the controls. 2. Multiple logistic regression analysis, including age, sex, BMI, waist to hip ratio, fasting serum glucose, lipids and insulin levels, HOMA IR, and hypertension showed that BMI, total cholesterol and HOMA IR were independently related with NAFLD. 3. 27% of the subjects with NAFLD showed metabolic syndrome, and 53% of subjects with metabolic syndrome had NAFLD. 4. The percentage of subjects who had more than two factors of metabolic syndrome was three times higher in the subjects with NAFLD compared to the controls. CONCLUSION: These results suggest that NAFLD may be independently related with insulin resistance. Metabolic diseases, such as glucose intolerance, obesity, dyslipidemia and hypertension, were more prevalent in the subjects with NAFLD than in the controls. Therefore, we should try to assess the status of the metabolic diseases, and treat them in patients with NAFLD.
Close layer

Endocrinol Metab : Endocrinology and Metabolism